Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY Sanofi daily Stock Chart
SNY [NYSE]
Sanofi
Index- P/E21.69 EPS (ttm)1.78 Insider Own16.40% Shs Outstand2.58B Perf Week0.76%
Market Cap99.71B Forward P/E13.09 EPS next Y2.96 Insider Trans0.00% Shs Float2.30B Perf Month-0.67%
Income4.66B PEG3.29 EPS next Q0.85 Inst Own10.30% Short Float0.14% Perf Quarter-6.28%
Sales38.28B P/S2.60 EPS this Y4.10% Inst Trans4.12% Short Ratio1.36 Perf Half Y0.34%
Book/sh23.61 P/B1.64 EPS next Y-3.11% ROA- Target Price51.67 Perf Year-13.60%
Cash/sh2.70 P/C14.32 EPS next 5Y6.60% ROE- 52W Range36.11 - 49.79 Perf YTD-5.52%
Dividend1.66 P/FCF- EPS past 5Y-4.40% ROI6.50% 52W High-24.01% Beta0.97
Dividend %4.29% Quick Ratio1.00 Sales past 5Y0.50% Gross Margin68.90% 52W Low4.76% ATR0.55
Employees115631 Current Ratio1.50 Sales Q/Q-4.40% Oper. Margin- RSI (14)37.54 Volatility1.00% 1.10%
OptionableYes Debt/Eq0.32 EPS Q/Q-9.90% Profit Margin- Rel Volume3.00 Prev Close38.67
ShortableYes LT Debt/Eq0.27 EarningsOct 28 BMO Payout- Avg Volume2.32M Price37.83
Recom2.30 SMA20-2.72% SMA50-5.12% SMA200-4.98% Volume6,977,906 Change-2.17%
Sep-23-16Initiated Piper Jaffray Neutral
Sep-15-16Resumed JP Morgan Underweight
Sep-13-16Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-16Upgrade Berenberg Hold → Buy
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Sep-29-16 03:04PM  Diabetes Care Market Expected to Offer Strong Growth for Novo Nordisk
01:34PM  The Diabetes Price War Claims Casualties at Bloomberg
01:24PM  The Highest-Yielding Drug Stocks at Motley Fool
Sep-28-16 08:03AM  3 Stocks to Avoid in Healthcare at Motley Fool
08:02AM  3 Top Dividend Stocks Selling for a Discount This Fall at Motley Fool
07:00AM  Looking Abroad for Quality Bargains at Morningstar
Sep-27-16 11:05AM  Pharmaceuticals Deal with End of Key Cystic Fibrosis Study
10:20AM  ETFs with exposure to Sanofi : September 27, 2016
09:30AM  The Zacks Analyst Blog Highlights: Teva Pharmaceutical Industries, Intel, Sanofi, Alphabet and Qualcomm
06:59AM  [$$] Corporate-Bond Buying Attracts Doubts as Growth Tool for Europe at The Wall Street Journal
Sep-26-16 04:32PM  Regeneron-Sanofi Could Beat Pfizer, Roche, AstraZeneca On Eczema
03:55PM  Regeneron, Sanofi Skin Disease Drug Under Priority Review
12:00PM  Sanofi gets $43 mln U.S. funding to spur Zika vaccine development
11:24AM  Pfizer: Split Decision at Barrons.com
10:05AM  Teva Pharmaceutical Leads in Global Generic Pharmaceutical Space
09:33AM  The Internet of Medical Things: 6 Stocks in Focus
07:15AM  FDA set to decide on two likely blockbuster drugs by Sanofi Genzyme at bizjournals.com
03:26AM  Sanofi may win U.S. approval of $3 billion eczema drug by March
03:24AM  Sanofi may win U.S. approval of $3 bln eczema drug by March Reuters
01:00AM  Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA PR Newswire
Sep-23-16 05:04PM  Youve Heard about the EpiPen Debacle, but Have You Heard This?
07:15AM  Coverage initiated on Sanofi by Piper Jaffray
Sep-22-16 11:12AM  Hard to swallow: emerging markets get tougher for drugmakers
10:33AM  Buffett Stock Wells Fargo Falls Close to 52-Week Low Post Scandal
09:56AM  New Setback for Sanofi's Lantus Increases Need for M&A
Sep-21-16 03:04PM  Cone Snail Venom Could Inspire Fast-Acting Insulin For Diabetes at Forbes
Sep-20-16 02:00PM  Sanofi Sues Merck Over Patent Infringement
12:09PM  The 5 Top-Selling Drugs In The World
12:19AM  Business Watch at The Wall Street Journal
Sep-19-16 06:46PM  Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap
11:19AM  [$$] Sanofi Files Suit Against Merck at The Wall Street Journal
10:47AM  Sanofi Fighting a Losing Battle, Sues Merck for Alleged Patent Infrigement
09:45AM  This Diabetes Breakthrough Is Great News or Terrible News, Depending on Your Perspective at Motley Fool
06:04AM  5 Things You Must Know Before the Market Opens Monday
Sep-17-16 03:00PM  There's something odd about the way insulin prices change
09:17AM  6 Flu Season Facts You Probably Don't Know at Motley Fool
Sep-16-16 10:30AM  Treatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzymes Lemtrada® (alemtuzumab) in Clinical Trials Business Wire
10:00AM  MNKD: How MannKind's Stock Price Fell 28% in 6 Months at Investopedia
09:04AM  Pharma Stock Roundup: Acquisitions & Deals Pick Up Pace, Aerie Up on Positive Data
08:04AM  Analyst Price Targets and Recommendations for Sanofi
12:02AM  A 93-year-old drug that can cost more than a mortgage payment tells us everything that's wrong with American healthcare
Sep-15-16 03:02PM  Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi (revised)
11:11AM  A 93-year-old drug that some children can't live without tells us everything that's wrong with American healthcare
11:04AM  Sanofis Chase for Zika Virus Vaccine Could Drive Its Share Price
10:45AM  Results from 1,000-Patient, Global Real-World Patient-Reported Outcomes Study of Sanofi Genzymes Aubagio® (teriflunomide) in Patients with Relapsing Multiple Sclerosis Demonstrate High Levels of Treatment Satisfaction Business Wire
10:04AM  Sanofis Rare Disease Franchise Continues to Be a Revenue Boon
08:22AM  Toujeo® Demonstrates a More Stable Profile and Lower Within-day Variability Compared to Insulin Degludec CNW Group
08:04AM  Will Sanofi See More Growth from Its Blockbuster Insulin Drug?
05:23AM  Negative-Yielding Corporate Debt: Good for Your Wealth? at The Wall Street Journal
Sep-14-16 06:04PM  How Sanofis Various Franchises Performed in 2Q16
04:04PM  How Sanofis Franchises Could Perform into 2017
02:08PM  Understanding Sanofis Discounted Valuation
09:14AM  Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi
Sep-13-16 03:21PM  Is This Lexicon Pharmaceuticals' Year? at Motley Fool
11:04AM  GSK Optimistic about Future of Its Consumer Healthcare Segment
10:04AM  GlaxoSmithKline Giving a Shot to Its Vaccines Business
07:43AM  Delving Into The Lexicon Pharmaceuticals, Inc. (LXRX) Data at Insider Monkey
07:00AM  Sanofi's Toujeo® Demonstrated a Consistently Lower Rate of Hypoglycemia Compared to Lantus® at All Levels of HbA1c control CNW Group
06:53AM  Sanofi's Toujeo(R) Demonstrated a Consistently Lower Rate of Hypoglycemia Compared to Lantus(R) at All Levels of HbA1c control PR Newswire
01:30AM  Bond Markets Hit Another 'Ukrainian Chicken Moment' at Bloomberg
12:09AM  [$$] Google Parent and Sanofi Name Diabetes Joint Venture Onduo at The Wall Street Journal
Sep-12-16 04:05PM  Sanofi, Google parent form $500 mln diabetes joint venture Reuters
11:33AM  Lexicon Hits 52-Week High on Positive Type I Diabetes Data
09:24AM  Why Novo Nordisk Stock Dropped 18.9% in August at Motley Fool
08:37AM  [$$] Google Parent and Sanofi Name Diabetes Joint Venture Onduo at The Wall Street Journal
08:31AM  Sanofi (SNY) forms Diabetes Joint Venture with Alphabet
08:00AM  Sanofi and Verily Life Sciences Announce Launch of Onduo, a Joint Venture to Develop Comprehensive Diabetes Management Platform PR Newswire
01:01AM  Pills and Pens Bring Hope for Drug Companies in Diabetes Crunch
01:00AM  Sanofi and Alphabet set up JV in diabetes Reuters
01:00AM  Alphabets Verily, Sanofi to Invest $500 Million in Diabetes at Bloomberg
Sep-11-16 07:02PM  Verily and Sanofi just launched a new company to tackle diabetes care
01:55PM  Sanofi, Google launch diabetes joint venture AFP
Sep-10-16 12:01AM  [$$] Junk Bonds Suddenly Look Vulnerable. Now What? at Barrons.com
12:01AM  [$$] Denmark's Novo Nordisk Plots a Recovery at Barrons.com
Sep-09-16 06:53PM  Why Finisar, Lexicon Pharmaceuticals, and Zumiez Jumped Today at Motley Fool
04:20PM  Why Lexicon Pharmaceuticals Skyrocketed 17% Today at Motley Fool
04:05PM  Sanofi-Backed Lexicon Diabetes Drug Scores In Type 1 Diabetes
10:25AM  Medivation (MDVN) Scales New 52-Week High on Pfizer Deal
09:45AM  Why Lexicon Pharma Is Soaring at 24/7 Wall St.
07:00AM  Drug Pricing Power Transcends Politics at Morningstar
Sep-08-16 01:23PM  MS Global Gains International Flavors, Coca-Cola
01:04PM  Why Is Sanofi Expanding in the CHC Space?
11:18AM  Understanding Sanofis Strategic Priority
11:18AM  Analyzing Sanofis Asset Swap Deal with Boehringer Ingelheim
Sep-07-16 12:55PM  [$$] Henkel/Sanofi: the positives of negatives at Financial Times
11:47AM  Sonofi, Henkel Issue Negative Yielding Bonds: Cause for Worry? at Barrons.com
09:50AM  Sanofi: One of the World's Greatest Stocks at Kiplinger
09:46AM  [$$] Takeda signals global ambitions with dengue vaccine trial at Financial Times
09:30AM  The Zacks Analyst Blog Highlights: Inovio Pharmaceuticals, OraSure Technologies, GlaxoSmithKline, Sanofi and Spectrum Brands
Sep-06-16 03:04PM  Here's Why Keryx Biopharmaceuticals Plunged 44.3% in August at Motley Fool
01:38PM  Inside the FDA: Why Sanofi SA (ADR) (SNY) IGlarLixi Was Delayed But Novo Nordisk A/S (ADR) (NVO) IDegLira Wasnt at Insider Monkey
08:38AM  Germanys Henkel Said to Market Bonds With Negative Yields at Bloomberg
05:00AM  Companies Get Paid to Borrow as Global Bond Binge Resumes at Bloomberg
Sep-03-16 08:00AM  Is EpiPen's Price The FDA's Fault? What's Holding Up New Generics?
Sep-02-16 05:10PM  EpiPen Price Relief Could Come From Rivals Before Politicians
03:11PM  Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians
08:04AM  Analyzing Eli Lillys Blockbuster Endocrinology Drugs
Sep-01-16 11:04AM  Why Pfizers Vaccines Business Is Declining
10:04AM  Regenerons Growth Opportunities: Praluent, Sarilumab, and Dupilumab
08:04AM  Restricted Access Continues to Impact Praluent Sales in 2016
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. It offers Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; Toujeo, an insulin glargine; and Afrezza, an inhaled insulin. The company also provides Praluent, a human monoclonal antibody; and Multaq, a multichannel blocker with anti-arrhythmic properties. In addition, it offers Cerezyme, an enzyme replacement therapy to treat gaucher disease; cerdelga, an oral therapy for Gaucher disease Type 1; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis Type 1, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for breast, prostate, gastric, lungs, and head and neck cancer treatment; Eloxatin for the treatment of stage III colon cancer; Thymoglobulin to treat acute rejection; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix/Iscover for atherothrombosis and acute coronary syndrome; Lovenox/Clexane for the treatment of venous thromboembolism; Aprovel/Avapro/Karvea for hypertension and nephropathy; Renagel/Renvela to treat chronic kidney disease; Allegra/Telfast to treat seasonal allergic rhinitis and uncomplicated hives; Stilnox/Ambien/Myslee for insomnia treatment; and Synvisc/Synvisc-One for the treatment of osteoarthritis pain. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJun 14Buy363.8664,73123,552,85923,418,396Jun 16 05:47 PM
Sanofi10% OwnerFeb 17Buy393.7180,00031,496,72823,353,665Feb 18 05:45 PM
Sanofi10% OwnerFeb 16Buy391.2381,15731,751,18223,273,665Feb 18 05:45 PM
Sanofi10% OwnerJan 12Buy465.0483,93839,034,66023,192,508Jan 14 05:46 PM
Sanofi10% OwnerNov 03Buy10.00900,0009,000,0003,218,899Nov 05 02:37 PM
Sanofi10% OwnerOct 06Buy472.3311,0405,214,51923,108,570Oct 08 05:50 PM
Sanofi10% OwnerOct 06Buy459.7180,53837,024,19723,097,530Oct 08 05:45 PM